Summit Therapeutics Inc. SMMT R3KPHARMA
Company Overview
Summit Therapeutics Inc., a biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies. Its lead development candidate is ivonescimab, a bispecific antibody for immunotherapy through blockade of PD-1 with the anti-angiogenesis for the treatment of non-small lung cancer (NSCLC) and colorectal cancer (CRC). The company has also combined ivonescimab with chemotherapy, which is in phase III clinical trial for the patients with epidermal growth factor receptor, mutated, and locally advanced or metastatic non-squamous NSCLC; first-line metastatic NSCLC; and first-line unresectable metastatic CRC. It markets its products in the United states, Canada, Europe, Japan, Latin America, Middle East, and Africa. The company was founded in 2003 and is headquartered in Miami, Florida.
Growth & Price Performance
Stock Price Performance
| 1 Year: | -35.69% |
| 6 Months: | +9.92% |
| 3 Months: | +22.47% |
| 1 Month: | +23.78% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- Price vs 200-DMAAbove
- RSI (14)68.21 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
No notable strengths flagged.
CONS
- Trading 36.0% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | SMMT Summit Therapeutics Inc. R3KPHARMA | 17.28 | -15.57 | $13.79B | 0.00% | - | - | - | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,123.91 | 37.80 | $1.00T | 0.60% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 269.12 | 31.22 | $648.55B | 1.98% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 248.78 | 70.48 | $439.62B | 2.78% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 148.46 | 118.77 | $366.28B | 2.31% | - | 6.96% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 400.84 | 25.74 | $359.79B | 2.47% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 137.70 | 20.80 | $261.73B | 3.36% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 160.04 | 23.99 | $248.20B | 2.00% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA | 603.02 | 32.49 | $222.97B | 0.29% | 8.14% | 13.51% | 8.81% | 12.95% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Sep 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 148.00K | 324.00K | 170.00K | 181.00K | 192.00K | 57.00K | 1.31M | 250.00K | 235.00K | 220.00K | 0 | 0 | 0 | - | - | 0 | - | - | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 568.44M | 234.21M | 224.88M | 195.21M | 220.50M |
| Operating Income | -6.19M | -9.34M | -15.36M | -16.94M | -16.92M | -23.73M | -19.49M | -22.16M | -12.69M | -16.94M | -537.15M | -15.79M | -20.49M | -42.39M | -59.62M | -58.38M | - | - | -568.44M | -234.21M | -224.88M | -195.21M | -220.50M |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -568.40M | -231.75M | -219.08M | -195.17M | -220.45M |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 9.00K | 0 | 0 | 0 | 0 | - | - |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -565.71M | -231.79M | -219.12M | -189.42M | -215.70M |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Net Income | -6.38M | -6.13M | -15.28M | -17.74M | -17.49M | -24.42M | -19.60M | -21.40M | -16.77M | -21.39M | -542.38M | -14.72M | -21.27M | -43.47M | -60.38M | -56.25M | - | - | -565.71M | -231.79M | -219.17M | -189.42M | -215.70M |
| Diluted EPS | -0.20 | -0.09 | -0.23 | -0.26 | -0.21 | -0.27 | -0.20 | -0.15 | -0.12 | -0.10 | -1.43 | -0.02 | -0.03 | -0.06 | -0.09 | -0.08 | - | - | -0.76 | -0.31 | -0.29 | -0.24 | -0.28 |
| R&D Expense | 9.95M | 12.91M | 13.57M | 13.73M | 18.38M | 23.92M | 19.94M | 20.56M | 9.01M | 17.05M | 9.88M | 9.45M | 15.32M | 30.87M | - | - | - | 51.27M | 208.02M | - | - | 132.62M | 157.73M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Jan 2019 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 57.09M | 743.00K | 860.00K | - | 705.00K | 0 | 0 | 0 |
| Cost of Revenue | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - |
| Operating Expenses | - | - | - | - | 64.33M | 88.73M | 210.98M | 1.09B |
| Operating Income | 5.39M | -27.47M | -53.19M | - | -63.62M | -88.73M | -210.98M | -1.09B |
| EBITDA | - | - | - | - | -73.12M | -598.27M | -212.53M | -1.08B |
| Interest Expense | - | - | - | - | 4.40M | 16.46M | 8.69M | 0 |
| Pretax Income | - | - | - | - | -78.78M | -614.93M | -221.30M | -1.08B |
| Tax Provision | - | - | - | 0 | - | - | - | - |
| Net Income | 10.87M | -29.13M | -52.70M | - | -78.78M | -614.93M | -221.31M | -1.08B |
| Diluted EPS | 0.63 | -0.89 | -0.76 | - | -0.41 | -0.99 | -0.31 | -1.44 |
| R&D Expense | 52.00M | 39.81M | 53.27M | 85.35M | 52.00M | 59.47M | - | - |
Balance Sheet (Annual)
Figures in USD.
| Metric | Jan 2018 | Jan 2019 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | - | 96.25M | 102.50M | - | 664.17M | 202.95M | 435.56M | 751.18M |
| Current Assets | - | - | - | - | - | 656.71M | 189.71M | 423.75M | 720.30M |
| Cash & Equivalents | - | - | 63.84M | 66.42M | - | 348.61M | 71.42M | 104.86M | 225.27M |
| Inventory | - | - | - | - | - | - | - | - | - |
| Receivables | - | - | - | - | 1.46M | 349.00K | 0 | - | - |
| Total Liabilities | - | - | 17.39M | 23.05M | - | 537.51M | 125.26M | 46.81M | 92.32M |
| Current Liabilities | - | - | 13.77M | 19.89M | - | 38.78M | 20.41M | 41.73M | 72.99M |
| Long Term Debt | - | - | - | - | - | 494.54M | 100.00M | - | - |
| Total Debt | - | - | - | - | - | 518.76M | 106.10M | 7.22M | 20.89M |
| Total Equity | -3.59M | 57.59M | 78.86M | 79.45M | - | 126.65M | 77.69M | 388.75M | 658.86M |
| Shares Outstanding | - | - | - | - | - | 211.09M | 701.66M | 737.63M | 775.37M |
Cash Flows (Annual)
Figures in USD.
| Metric | Jan 2019 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -35.11M | -20.76M | -48.11M | - | -41.58M | -76.76M | -142.11M | -322.93M |
| Investing Cash Flow | -331.00K | -341.00K | -421.00K | - | -624.00K | -587.77M | -205.34M | -174.31M |
| Financing Cash Flow | 44.51M | 49.51M | 50.55M | - | 620.24M | 86.51M | 381.23M | 617.53M |
| Capital Expenditure | -157.00K | -205.00K | -421.00K | - | -624.00K | -128.00K | -139.00K | -657.00K |
| Free Cash Flow | -35.26M | -20.96M | -48.53M | - | -42.21M | -76.89M | -142.25M | -323.59M |
| Net Change in Cash | - | - | - | - | 578.04M | -578.02M | 33.78M | 120.29M |
| Dividends Paid | 0 | 0 | 0 | - | - | - | - | - |
Ratios (Annual)
Figures in %.
| Metric | Jan 2019 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - | - | - |
| Operating Margin % | 9.4% | -3,697.6% | -6,185.2% | - | -9,024.3% | - | - | - |
| Net Margin % | 19.0% | -3,920.2% | -6,127.6% | - | -11,174.8% | - | - | - |
| ROE % | 18.9% | -36.9% | -66.3% | - | -62.2% | -791.5% | -56.9% | -163.9% |
| ROCE % | - | -33.3% | -64.4% | - | -10.2% | -48.6% | -53.6% | -161.4% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Baker Bros. Advisors, LP | 4.11% | 32.79M | $585.24M |
| 2 | FMR, LLC | 1.26% | 10.04M | $179.28M |
| 3 | State Street Corporation | 1.20% | 9.54M | $170.23M |
| 4 | Blackrock Inc. | 1.19% | 9.53M | $170.09M |
| 5 | Vanguard Capital Management LLC | 0.72% | 5.73M | $102.36M |
| 6 | UBS Group AG | 0.66% | 5.23M | $93.42M |
| 7 | Vanguard Portfolio Management LLC | 0.63% | 5.04M | $90.00M |
| 8 | Goldman Sachs Group Inc | 0.57% | 4.51M | $80.56M |
| 9 | Price (T.Rowe) Associates Inc | 0.49% | 3.89M | $69.50M |
| 10 | Point72 Asset Management, L.P. | 0.46% | 3.70M | $66.01M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for SMMT
Why Is SMMT Stock Tumbling Today? - Stocktwits
<a href="https://news.google.com/rss/articles/CBMinAFBVV95cUxQTlhuRnNfVWRVOWZCX0g1TFhOLUVaMHJmVmhHRjlrYXpnSnk1a1ZSS3djdTExZGpILWdDdjdSMi1GclBUclZvRmlmSHhEZDB6Y3hzUnl5amE0NXZXQkdqQWZPQTM2cWxmN3NEVnkwQlJKaXhsbFhpRmp4YWl1Zkp2eFQ2aEtGYWhZRE1vXz…
SMMT Stock Soars on NSCLC Drug Survival Data Beating Keytruda in China - finance.yahoo.com
<a href="https://news.google.com/rss/articles/CBMikgFBVV95cUxQWDhReHh6RjE0OE1kNzNNSDhjQkJMUzBkTWtyeVpqQlJFYk1ONGVGMEhsLW12b3ZhY2NKaDl4VGcwSnJNamJpdFVDWHFNN1VsRTdicmNrQ1dMMU1fbzJob0NvSGs1TXI3U1lyc1F2Unh3alN2el82ZkdjcjdKSGFCaHFjRTJXdEUwSk5Uek…
SUMMIT THERAPEUTICS INC (SMMT) Stock Chart - ChartMill
<a href="https://news.google.com/rss/articles/CBMiZEFVX3lxTE9qelp3cVRTWFlORlYzQ2RxenNtaDQwMmxJMXFXVjBOcGVOejlEZEdmdlhzWW5zdmZtdENCOFBlWm1vNmNlaFFDOWhSRzRvZHRZSWJLVnFZOG9XbW81ZzN5MEpEMFI?oc=5" target="_blank">SUMMIT THERAPEUTICS INC (SMMT) S…
Summit Packs A Punch For Merck's Keytruda — But Not Everyone Is Sold - Investor's Business Daily
<a href="https://news.google.com/rss/articles/CBMimgFBVV95cUxQTUtFX0F6LXFQNGt4VjY3U292Z3NvVlhaRU80TUV5MkxfdWF6RXZ5azhSRU5CbU5raGgyOVQ2dHRBV0NvMzI3Y3pkRDI2YUFVLWFiTGNIUU85YktPa3l1eURudnJXbHN5RndzcXozMkZSeWtIQWlyUXduMDJEaFFBSkZOTEQ0VEdyWTN0RE…
Summit Therapeutics (SMMT) Stock Looks Stretched On Fresh Lung Cancer Data - finance.yahoo.com
<a href="https://news.google.com/rss/articles/CBMingFBVV95cUxPUGtQcUlkX2NxVm9NOXAwUC1iMlJCUGF0UU9oN0l2RkUyZDdSU1lJVVN5UVRFdFpyZkVHdW5hYjFCYVFYZE5YWVhGa2ZmTk1rLVFudC1fcHFyXzVnR3lkT1FJaGo4a25udXE5NnlRcTJIdkV1NTRpRDA4b2t5TTRCdHByU21zUER6VGIzST…
Why Summit Therapeutics (SMMT) Is Up 19.5% After New Ivonescimab Phase III Survival Data - And What's Next - simplywall.st
<a href="https://news.google.com/rss/articles/CBMi6AFBVV95cUxOSXRjZDlweUduOUlmakg1QzNUSGJYcHYxdFYwNVFzbk9iYjh5ejlQS3FBcHV3ZGxuQ1ZERjJyUkVTNGVlRmd3REc3a0NUdXdKLUtobXpzM0ZPTno4bkFDRFZfZHBkR3dTQTFORHFfVVNMSmJNdjRoVjhTcGN0NDZqa0xlLU44LVFyTHh6bk…
SMMT — Frequently Asked Questions
What is the current share price of Summit Therapeutics Inc. (SMMT)?
As of 2026-09-19 21:16 PDT, Summit Therapeutics Inc. (SMMT) trades at $17.28 on NasdaqGM. Its 52-week range is $12.43 to $26.98.
What is the market capitalisation of SMMT?
Summit Therapeutics Inc. (SMMT) has a market capitalisation of $13.79B on NasdaqGM.
What is the P/E ratio of SMMT?
SMMT trades at a trailing price-to-earnings (P/E) ratio of -15.57. The industry average P/E is 24.83. Its price-to-book (P/B) ratio is 22.48.
Is SMMT a good stock to buy?
This page provides a data-driven analysis of Summit Therapeutics Inc. (SMMT), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.